Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Chinese Journal of Oncology ; (12): 68-72, 2012.
Article in Chinese | WPRIM | ID: wpr-335341

ABSTRACT

<p><b>OBJECTIVE</b>The aim of this study was to discuss the clinical effectiveness of high intensity focused ultrasound (HIFU) combined with gemcitabine administered by intra-arterial infusion on intermediate and advanced pancreatic cancer.</p><p><b>METHODS</b>Forty-eight patients with intermediate and advanced pancreatic cancer were divided into two groups. Twenty-four patients of the experimental group were treated by HIFU combined with gemcitabine, and 24 patients of the the HIFU group were treated by HIFU alone. Then the curative effect, extent of pain relief, and survival time were compared in the course of the treatment between the two groups.</p><p><b>RESULTS</b>As compared with those in the control group, the overall response rate, level of pain relief, and 12-month survival rate after therapy were higher and the median survival time was longer in the joint group (P < 0.05).</p><p><b>CONCLUSIONS</b>Ultrasound imaging, CT and associated tumor marker detection can make effective measurement to evaluate curative effect on pancreatic carcinoma. HIFU plus gemcitabine administered by intra-arterial infusion can improve the clinical therapeutic efficacy, pain relief, quality of life and long-term survival rate of patients with pancreatic cancer.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antimetabolites, Antineoplastic , Therapeutic Uses , Combined Modality Therapy , Deoxycytidine , Therapeutic Uses , Disease Progression , Follow-Up Studies , High-Intensity Focused Ultrasound Ablation , Infusions, Intra-Arterial , Neoplasm Staging , Pain Management , Pancreatic Neoplasms , Diagnostic Imaging , Drug Therapy , Therapeutics , Quality of Life , Remission Induction , Survival Rate , Ultrasonography
2.
Chinese Journal of Hematology ; (12): 1000-1003, 2012.
Article in Chinese | WPRIM | ID: wpr-323505

ABSTRACT

<p><b>OBJECTIVE</b>This research was aimed to evaluate the immune mechanism and clinical effect of immunotherapy of dendritic cells (DC) and cytokine-induced killer cell (CIK) combined with chemotherapy on multiple myeloma (MM).</p><p><b>METHODS</b>60 patients with MM were randomly divided into two groups. 30 patients in chemotherapy group were treated by chemotherapy only, 30 patients in joint group were treated by adoptive immunotherapy (DC-CIK) combined with chemotherapy. A variety of immunological indexes (Hsp70, Th1/Th2, TGF-β) of all patients before and after chemotherapy were recorded; Also the clinical outcomes between two groups were compared.</p><p><b>RESULTS</b>After chemotherapy, the immunological indexes of all patients were better than those of before chemotherapy (P < 0.05); After treatment, quality of life, clinical index and survival in joint group were better than in chemotherapy group (P < 0.05).</p><p><b>CONCLUSION</b>Chemotherapy could break the immunosuppression of MM and improve the anti-tumor response of DC-CIK; Chemotherapy and DC-CIK may have synergistic effect for MM.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Combined Modality Therapy , Cytokine-Induced Killer Cells , Allergy and Immunology , Dendritic Cells , Allergy and Immunology , Immunotherapy, Adoptive , Multiple Myeloma , Allergy and Immunology , Therapeutics , Treatment Outcome
3.
Journal of Experimental Hematology ; (6): 219-223, 2010.
Article in Chinese | WPRIM | ID: wpr-328540

ABSTRACT

This study was aimed to investigate the killing activity of cytokine-induced killer (CIK) cells after being incubated with autologous tumor cell lysate-pulsed dendritic cells (DC) and to evaluate the clinical efficacy and side effect of autologous tumor cell lysate-loaded DC in combination with CIK on relapsed or refractory non-Hodgkin's lymphoma (NHL). Peripheral blood mononuclear cells (PBMNC) were isolated from 9 patients with NHL, and cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) to produce DC. The DC were pulsed with autologous tumor cell lysate. T lymphocytes from PBMNC were cultured with interferon-gamma (IFN-gamma), IL-2, CD3-moAb, and IL-1alpha to prepare CIK. After receiving the immunotherapy of DC and CIK, immunologic and clinical responses were evaluated. The results showed that the AgNOR, CD3(+)CD8(+) and CD3(+)CD56(+) ratio were markedly improved after the immunotherapy (p < 0.01); IFN-gamma and IL-12 levels in supernatant of DC-CIK group were higher than that in CIK group (p < 0.01); Tumor size were significantly decreased after the immunotherapy (p < 0.05). Except transient fever and chill, no remarkable adverse event happened during or after the treatment. It is concluded that the autologous tumor cell lysate-pulsed DC in combination with CIK show ability to specifically kill the lymphoma cells, obviously increases the IS value of Ag-NOR in peripheral lymphocytes, secretes cytokines higher than CIK cells alone. This combination displays the short-term satisfied efficacy on NHL through inducing specific antitumor immunity, and can be used as an effective adjuvant measure for the routine therapy of NHL.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Cytokine-Induced Killer Cells , Allergy and Immunology , Dendritic Cells , Allergy and Immunology , Immunotherapy , Immunotherapy, Adoptive , Lymphoma, Non-Hodgkin , Allergy and Immunology , Therapeutics , Recurrence , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL